Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). although relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma. Accordingly. great interest exists in developing CAR T cells directed against alternative le... https://thebanyantreers.shop/product-category/buffet/